Abstract: Liquid biopsy provides minimally invasive and readily obtainable access to tumor-associated biological material in blood or other body fluids. These samples provide important insights into cancer biology, such as primary tumor heterogeneity; real-time tumor evolution; response to therapy, including immunotherapy; and mechanisms of cancer metastasis. Initial biological materials studied were circulating tumor cells and circulating nucleic acids, including circulating tumor DNA and microRNAs; more recently, studies have expanded to investigate extracellular vesicles, such as exosomes, microvesicles, and large oncosomes; tumor-derived circulating endothelial cells; and tumor-educated platelets. Even with an ongoing ambitious investment effort to develop liquid biopsy as an early cancer detection test in asymptomatic individuals, current challenges remain regarding how to access and analyze rare cells and tumor-derived nucleic acids in cancer patients. Technologies and associated bioinformatics tools are continuously evolving to capture these rare materials in an unbiased manner and to analyze them with high confidence. After first presenting recent applications of liquid biopsy, this review discusses aspects affecting the field, including tumor heterogeneity, single-cell analyses, and associated computational tools that will shape the future of liquid biopsy, with resultant opportunities and challenges.
T he term liquid biopsy originally referred to the clinical use of blood samples for the capture and study of circulating tumor cells (CTCs) to monitor cancer patient treatment response and for marker detection associated with sensitivity or resistance to specific therapies. 1 More recently, liquid biopsy encompasses myriad assays that measure tumor-derived cells or products in blood and other body fluids that, in general, may be obtained serially and easily with minimal patient risk. Most commonly studied are CTCs and circulating nucleic acids, such circulating tumor DNA (ctDNA) and microRNAs. 2 However, the liquid biopsy field also comprises analyses of extracellular vesicles, including exosomes, microvesicles, large oncosomes, and apoptotic bodies. [3] [4] [5] [6] [7] [8] [9] [10] In addition to distinct populations of immune-derived cells, [11] [12] [13] other cells in circulation garnering particular interest are tumor-derived circulating endothelial cells 14, 15 and tumor-educated platelets. [16] [17] [18] LIQUID BIOPSY: MULTIFACETED APPLICATIONS
Tissue biopsy provides a snapshot of genetic alterations at the time of sampling. The information gleaned from such an approach is of limited use over time, as tumors constantly evolve to become highly heterogeneous. The tissue sample itself may represent a single geographic location within a heterogeneous tumor, and shed cells may form secondary or tertiary metastases, which themselves become heterogeneous because of differences in microenvironmental cues and/or drug selection pressures and then seed further metastases. 19, 20 Longitudinal tracking of genetic and epigenetic alterations relevant to cancer through liquid biopsy is highly desirable for multiple applications, which include assessment of molecular heterogeneity of primary and secondary tumors, identification of genetic determinants for targeted therapy, cancer surveillance and monitoring for relapse, monitoring treatment response (chemotherapy, radiation therapy, and immunotherapy), assessment of resistant tumor evolution in real time because of treatment pressure, and an aspiring application to screen asymptomatic individuals for early detection of cancer (Fig. 1) .
Blood is the most widely used body fluid for liquid biopsy. However, other body fluids such as urine, tears, saliva, pleural effusions, and cerebrospinal fluid harbor tumor-derived nucleic acid, cells, and/or other materials. 2, 21 Sampling of blood or body fluids that directly drain tumor sites may yield higher quantities of CTCs or DNA of tumor origin than peripheral blood or plasma. 22, 23 For example, in patients with multiple types of primary and metastatic brain tumors, cerebrospinal fluid showed higher concentration of ctDNA than plasma for disease restricted to the brain and meninges (in contrast to high tumor burden from visceral disease, which was then reflected in plasma ctDNA). Cerebrospinal fluid ctDNA was more representative of genomic alterations in the brain, a site difficult to perform a biopsy on, than plasma, and showed potentially actionable mutations not present in plasma. 23 Recently, another interesting body fluid was added to the list. Researchers at Children's Hospital Los Angeles reported detection of ctDNA in aqueous humor, the clear fluid between the cornea and the lens of the eye, in pediatric patients with retinoblastoma undergoing enucleation or intravitreous drug injections. 24 Using whole-genome sequencing of ctDNA, the authors were able to identify copy number variations that were representative of the tumors. The authors noted that they were not successful in finding CTCs in aqueous humor and blood, or ctDNA in blood.
Currently, there is an ambitious program underway sponsored by GRAIL, Inc., called the Circulating Cell-free Genome Atlas Study (ClinicalTrials.gov identifier NCT02889978) that proposes to collect deidentified biospecimens and clinical data from 10,500 subjects with multiple types of malignancies and from 4500 representative subjects without cancer to develop and evaluate models that distinguish cancer and noncancer, as well as tissue of origin. 25 It is hoped that deep sequencing of circulating cell-free nucleic acids will provide useful information for future development of assays geared toward early detection of cancer.
In another trial, the STRIVE study (ClinicalTrials.gov identifier NCT03085888), GRAIL is hoping to prospectively enroll 120,000 participants who are undergoing screening mammography and will perform high-intensity sequencing to characterize cell-free nucleic acids that classify cancer from noncancer, again with the aim of developing a blood test for the early detection of breast cancer. 26 Other groups have demonstrated the capability of circulating microRNA as markers for diagnosing early-stage ovarian 27 and gastrointestinal 28 cancer.
SINGLE-CELL ANALYSIS TO DECIPHER TUMOR HETEROGENEITY
Cancer is a complex disease that is characterized by high diversity among different cancers (intertumor heterogeneity) and within a single tumor (intratumor heterogeneity). Intertumor heterogeneity is the basis for the molecular classification of cancer. [29] [30] [31] Single-cell analysis shines limited light on intertumor heterogeneity, and hence it is not well suited to answer many questions related to cancer classification. However, single-cell analysis plays a crucial role in deciphering intratumor heterogeneity, as clearly demonstrated by multiregion sequencing of primary tumor and comparison to metastatic foci. 32, 33 In addition to tissue biopsy, CTCs and ctDNA are used to understand the intratumor heterogeneity of primary tumor and metastatic disease progression. 34 However, it is worth noting that although liquid biopsy alone cannot completely dissect interlesion heterogeneity, 20 single-cell profiling of CTCs shed from primary and/or metastatic tumors displays heterogeneity among individual CTCs even within a single blood draw, and in cases of advanced disease, this may reflect the diversity of tumor cells remaining that would require further treatment. 35 Although CTCs and ctDNA are considered complementary approaches to liquid biopsy, and use of ctDNA is fast gaining in popularity because of the relative ease of sample preparation compared with technical challenges in capturing rare cancer cells, there are still some potential advantages for analyzing CTCs. First, while CTCs and ctDNA are both present in blood containing high background of nonspecific biological materials such as white blood cells (WBCs) and normal or non-tumor-derived genomic DNA that comprises the majority of circulating cell-free DNA (cfDNA), enriching for CTCs from blood will increase the signal-to-noise ratio. Second, functional assays are possible on enriched viable CTCs, including propagation in vitro and in vivo. In contrast, there still exist numerous technical challenges due to the presence of huge background DNA, in the determination of ctDNA alterations. In a large study using a targeted gene panel, more than 37% of patients with multiple types of cancer had no detectable ctDNA test alterations, and 24% had variants of unknown significance. 36 Other studies have revealed cases of metastatic cancer in which one ctDNA marker shows evidence of treatment response, whereas another may remain abnormally high, suggesting metastatic heterogeneity and that current treatment was only ablating a portion of the cancer cells. 37 Future drug testing of any residual live cells would be a valuable tool for selecting follow-on therapeutic regimen. Typically, targeted sequencing of ctDNA for known cancer-related genes is performed, although this approach might restrict detection of novel mutations. 38 Viable CTCs correlate with existing live tumor burden, whereas ctDNA concentration is thought to be generally associated with tumor death: it is posited that ctDNA is released from dying cancer cells either by apoptosis or necrosis, 39, 40 although others have argued that viable cancer cells may also release ctDNA. 41 As the half-life of ctDNA is only less than 2 hours, 40, 42 timing of blood collection relative to chemotherapy dosing may impact its measurement. Finally, thresholds for ctDNA response to a therapy remain to be standardized. Despite these limitations, it has been demonstrated that, when measurable, ctDNA nicely reflects tumor burden. 43 Approximately 10% to 20% of patients with non-small cell lung cancer (NSCLC) have epidermal growth factor receptor (EGFR) mutations and may be candidates for EGFR tyrosine kinase inhibitor therapy. Thus, the cobas EGFR Mutation Test v2 has recently been US Food and Drug Administration-approved for identifying patients with NSCLC who may harbor EGFR mutations, including the T790M mutation, which would make them candidates for different EGFR tyrosine kinase inhibitor therapies (note that the test is approved for patients with tumors not amenable to biopsy because of the 40% false-negative rate associated with this test). [44] [45] [46] However, most lung cancers and other tumors do not contain actionable mutations that would specify a particular therapy. Although mutations may exist at the single-cell level, ctDNA reflects an amalgam of DNA released from mutationally heterogeneous populations of cancer cells. Thus, the concept of ctDNA alteration thresholds will become important. Finally, a critical concept for clinical utility of either liquid biopsy component will be in determining which drugs can be used to target specific tumor biological features or pathways in residual cancer cells. Live residual CTCs can potentially reveal this heterogeneous biology, which might then affect choice of specific and combinational treatments.
Multiple authors have demonstrated clear biological heterogeneity within tumor tissue using single-cell RNA sequencing (RNAseq). Patel et al. 47 analyzed 430 single cells obtained directly from 5 primary glioblastomas and reported extensive intratumoral heterogeneity in regulatory programs key to glioblastoma biology. Similarly, Tirosh et al. 48 used RNA-seq to analyze 4645 single cells isolated from 19 patients and profiled malignant, immune, stromal, and endothelial cells. The authors noted that malignant cells within the same tumor displayed transcriptional heterogeneity associated with the cell cycle, spatial context, and a drug-resistance program. Tumor-infiltrating T cells showed exhaustion and variability across patients. The biological heterogeneity identifiable through transcriptional and proteomic profiling of individual CTCs shed from residual tumor still in the body may elucidate combinations of therapies that should be tried. We also expect that in the future live CTCs themselves might be individually assayed and/or propagated for drug testing or drug discovery. 
CTC ENRICHMENT FOR SINGLE-CELL ANALYSIS
For CTCs, there are numerous enrichment technologies (some commercial) with different pros and cons. 49, 50 These technologies can be broadly binned into 2 categories: affinity based and label-free. Label-free approaches are desirable because they are less biased in enrichment with respect to surface marker selection, but instead depend on size or density selection of CTCs or their intrinsic dielectric properties. Toner's group reported an inertial focusing-enhanced microfluidic CTC capture platform, also known as the "CTC-iChip," which can operate in a tumor epitope-independent manner. 51 In this platform, the nucleated WBCs (tagged with magnetic beads) and CTCs are separated from red blood cells by using deterministic lateral displacement. Subsequently, the nucleated cells are directed to a microfluidic channel using inertial focusing, and finally WBCs are depleted by applying a magnetic field. Extensive validation of this platform has been demonstrated for breast, 52 pancreas, 53 and prostate cancer. 54 Recently, Nagrath's group reported a label-free microfluidic platform, known as Labyrinth, which uses enhanced Dean flow fractionation to enrich CTCs from breast cancer blood samples. 55 The authors analyzed the gene expression of these enriched CTCs using a targeted TaqMan-based stem cell gene signature panel on C1™ Single-Cell Auto Prep system and BioMark™ System (Fluidigm, South San Francisco, CA ). Commercial label-free microfluidic systems for CTC enrichment include ClearCell FX1 System (Clearbridge BioMedics, Singapore), ApoStream technology (ApoCell, Houston, TX), VTX-1 platform (Vortex Biosciences, Menlo Park, CA), the C-Prep Genesis (Celsee Diagnostics, Plymouth, MI), the Liquid Biopsy Platform (Cynvenio, Westlake Village, CA), and the Parsortix System (ANGLE, Surrey, UK), as well as multiple filter-based systems such as ISET (Rarecells Diagnostics, Paris, France), ScreenCell (ScreenCell, Sarcelles, France), CellSieve (Creatv MicroTech, Potomac, MD), and faCTChecker (Circulogix Inc., Miami, FL). Ramalingam et al. 56 integrated ClearCell FX System with the Polaris™ system (Fluidigm, South San Francisco, CA) and analyzed the full-length mRNA expression profiles of individual CTCs from triple-negative and estrogen receptor-positive/ progesterone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients. O'Shannessy et al. 57 used the dielectrophoresis-based ApoStream system to isolate CTCs from multiple epithelial cancers and confirmed the expression of folate receptor α in CTCs from NSCLC lung, breast, and ovarian cancer patients. Powell et al. 35 transcriptionally profiled single CTCs from the blood of women with aggressive primary and metastatic breast cancer using 87 cancer-associated and reference genes, finding a subset of 31 highly expressed genes that distinguished different subpopulations of CTCs; these included genes associated with metastasis (NPTN, S100A4, S100A9) and epithelial-mesenchymal transition (VIM, TGFß1, ZEB2, FOXC1, CXCR4). 35 Moreover, the expression profiles of single CTCs were markedly distinct from that of single cancer cells from cell lines or primary breast cancer cultures. In contrast, Pixberg et al. 58 analyzed DNA methylation patterns in individual CTCs from patients with metastatic breast and castration-resistant prostate cancer. They reported epigenetic heterogeneity among CTCs, but surprisingly noted a relative lack of methylation at the promoter regions of 3 EMT-suppressing genes when inactivation by promoter hypermethylation was expected. This suggests that more work needs to be done on global epigenetic analyses to understand tumor cell shedding and metastasis at the single-cell level.
Recently, Liu et al. demonstrated a targeted sequencing workflow, optimizing DNA extraction methods and evaluating wholegenome amplification methods for use with targeted next-generation sequencing (NGS) panels on rare pooled CTCs from the blood of patients with metastatic colorectal cancer, captured label-free using laminar microvortices in a microfluidic device. 59 This same label-free platform captured fresh CTCs for individual cell analysis using a single-cell multiplex protein assay. 60 
SENSITIVITY ISSUES
Technologies for ctDNA detection are based on either polymerase chain reaction (PCR) or NGS. The sensitivity of PCR (approximately 1%) and its variant (droplet digital PCR; sensitivity ≤0.01%) is better when compared with NGS-based methods (approximately 2%). 40 Oxnard's group implemented Bio-Rad Laboratories' droplet digital PCR into clinical practice for detection of KRAS and EGFR mutations in blood for NSCLC patients and suggested that an EGFR T790M mutation that may be missed by tissue genotyping of a heterogeneous tumor may be detected in plasma. 61 To improve the sensitivity of NGS-based methods, researchers added an additional PCR-based preamplification step prior to library preparation. This preamplification step improved the mutation detection down to 0.6% allele frequency from 1.6 ng DNA input for a previously published microfluidic multiplex PCR-based target enrichment method. 62 New methods to determine the tissue of origin of ctDNA are emerging based on DNA methylation patterns 63 or nucleosome positioning. 39 
BIOINFORMATICS TOOLS FOR LIQUID BIOPSY
Single-cell/CTC variant callers have many pitfalls, as these analysis tools were originally developed for bulk sequencing data analyses. Current variant callers such as VarScan 2, 64 Genome Analysis Tool Kit, 65 and the Bayesian classifier method for very low allele fraction mutation detection, MuTect, 66 do not account for allelic dropout, coverage nonuniformity, allelic imbalance, and false-positive sequencing errors, which are characteristics of single-cell DNA sequencing data. Monovar is a unique variant caller specifically developed to analyze single-cell data to detect and genotype single-nucleotide variants. 67 Recently, researchers reported SiNVICT (single-nucleotide variant and indel caller for ctDNA), a computational method designed for sensitive and specific analysis of tumor-derived ctDNA, including ctDNA originating from multiple tumor subclones within a background of non-tumor-related circulating cfDNA. It detects single-nucleotide variants and indels at very low variant allele percentages (as low as 0.5%) in situations of very high read depth and very low dilutions by accounting for false positives from mapping errors and other artifacts, including strand bias and low base quality at read ends. 68 Filtering data by applying suitable criteria such as read coverage, sequencing quality score (e.g., Q20 indicates a 1 in 100 incorrect base call or an inferred base call accuracy of 99%), percentage reads mapped to genome, is important for single-cell analysis. These criteria are subjective among research groups, and there is no standard for analysis filters. In addition, current methods for whole-genome amplification are not perfect, and most existing methods introduce some amplification bias and chimeric DNA rearrangement. Hence, it is essential to optimize workflow to reduce bias and improve the read coverage. 59 For single-cell gene expression profiling, typical pitfalls include low mRNA capture efficiency, dropouts, and incorrect global normalization methods. In the last few years, there has been a huge surge in single-cell analysis platforms. Broadly, the chemistry for single-cell mRNA-seq can be categorized as either full-length mRNA-seq or end-counting methods (3′ and 5′ endcounting). The mRNA capture efficiency for CEL-Seq (cell expression by linear amplification and sequencing) protocol is approximately 3% 69 and approximately 7% for inDrop (indexing droplets), 70 suggesting that these methods may detect only medium to highly abundant transcripts. The best reported capture efficiency is for Smart-seq2 full-length mRNA-seq protocol (approximately 20%), 71 also confirmed to be the most sensitive but somewhat more costly in a systematic comparison of multiple single-cell RNA-seq technologies. 72 These data indicate that a majority of expressed transcripts in single cells may not be detected by current methods. Other high-throughput droplet-based methods may be used to generate transcriptomic data for thousands of single cells, as in the study of immune cell subpopulations from blood or bone marrow. 73 Computational methods are also heavily used to understand the concordance in mutation profile between cfDNA and tumor tissue. Toward this, Adalsteinsson et al. 74 reported ichorCNA, a software that quantifies the fraction of tumor-derived DNA in cfDNA without prior knowledge of tumor mutations by utilizing ultralow-pass whole-genome sequencing to analyze somatic copy number alterations. In 1439 blood samples from 520 patients with metastatic breast or prostate cancer, the authors noted that 34% of patients had sufficient (≥10%) tumor-derived DNA to perform standard depth whole-exome sequencing (WES), allowing an untargeted approach to ctDNA analyses and showing high concordance between WES of ctDNA and metastasis tissue. 74 In a prior work, the same group performed WES on individual CTCs from patients with metastatic prostate cancer using a census-based sequencing approach, where a sample was sequenced by preparing multiple independent individual CTC libraries, each exhibiting nonuniform coverage, with variants called only if present in multiple libraries. This approach works only for patients with at least 5 CTCs and emphasizes early metastatic trunk mutations over private mutations as the latter, which may be present in single CTCs, are difficult to differentiate from sequencing errors associated with low input DNA. 75 
CONCLUSIONS-OPPORTUNITIES AND CHALLENGES
Liquid biopsy is an active and advancing field, academically and commercially. There are many new platforms still being developed and tested for isolation and analysis of populations of circulating cells, nucleic acids, and extracellular vesicles, and especially pertinent, investigations of ways in which these cells or tumor products interact with normal tissue, cancerous tissue, and, importantly, immune cells in tissue, bone marrow, and bloodstream, and how this interaction may be leveraged for optimizing cancer care.
However, despite excellent demonstration of potential clinical applicability and promise, studies showing evidence of clinical utility of liquid biopsy to change or reject a therapy are still ongoing. Liquid biopsy in its current format remains an investigational tool. Part of the reason lies in the dearth of therapies for end-stage and generally chemoresistant cancers: earlier diagnosis of dismal disease does not impact clinical outcome when patients are switched from one ineffective therapy to another ineffective, and potentially more toxic, therapy. There is, however, hope that newer immunotherapies and drugs that affect the tumor microenvironment will change the therapeutic landscape and increase response to therapy.
That said, liquid biopsy will most certainly play an important and evolving role in the future diagnosis and care of cancer patients.
